410 related articles for article (PubMed ID: 24633966)
1. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.
Porten S; Siefker-Radtke AO; Xiao L; Margulis V; Kamat AM; Wood CG; Jonasch E; Dinney CP; Matin SF
Cancer; 2014 Jun; 120(12):1794-9. PubMed ID: 24633966
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Chemotherapy Benefits Survival in High-Grade Upper Tract Urothelial Carcinoma: A Propensity Score-Based Analysis.
Chen L; Ou Z; Wang R; Zhang M; He W; Zhang J; Zu X; Yi L; Xu R; Jiang S; Qi L; Wang L
Ann Surg Oncol; 2020 Apr; 27(4):1297-1303. PubMed ID: 31853757
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis.
Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF
Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM
J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680
[TBL] [Abstract][Full Text] [Related]
5. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience.
Cutress ML; Stewart GD; Wells-Cole S; Phipps S; Thomas BG; Tolley DA
BJU Int; 2012 Dec; 110(11):1608-17. PubMed ID: 22564677
[TBL] [Abstract][Full Text] [Related]
6. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.
Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V
Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254
[TBL] [Abstract][Full Text] [Related]
7. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study.
Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M
Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.
Lynch SP; Shen Y; Kamat A; Grossman HB; Shah JB; Millikan RE; Dinney CP; Siefker-Radtke A
Eur Urol; 2013 Aug; 64(2):307-13. PubMed ID: 22564397
[TBL] [Abstract][Full Text] [Related]
9. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma.
Kim JK; Moon KC; Jeong CW; Kwak C; Kim HH; Ku JH
Urol Oncol; 2017 Jul; 35(7):458.e9-458.e15. PubMed ID: 28347659
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
11. Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
Zennami K; Sumitomo M; Takahara K; Nukaya T; Takenaka M; Fukaya K; Ichino M; Fukami N; Sasaki H; Kusaka M; Shiroki R
BJU Int; 2021 Mar; 127(3):332-339. PubMed ID: 32896105
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
D'Andrea D; Matin S; Black PC; Petros FG; Zargar H; Dinney CP; Cookson MS; Kassouf W; Dall'Era MA; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; Sridhar SS; North S; Barocas DA; Lotan Y; Stephenson AJ; van Rhijn BW; Spiess PE; Daneshmand S; Shariat SF
BJU Int; 2021 May; 127(5):528-537. PubMed ID: 32981193
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
14. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
Hosogoe S; Hatakeyama S; Kusaka A; Hamano I; Iwamura H; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Yoneyama T; Hashimoto Y; Koie T; Ohyama C
Eur Urol Focus; 2018 Dec; 4(6):946-953. PubMed ID: 28753881
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.
Leow JJ; Martin-Doyle W; Fay AP; Choueiri TK; Chang SL; Bellmunt J
Eur Urol; 2014 Sep; 66(3):529-41. PubMed ID: 24680361
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma.
Martini A; Falagario UG; Waingankar N; Daza J; Treacy PJ; Necchi A; Galsky MD; Sfakianos JP
Urol Oncol; 2020 Aug; 38(8):684.e9-684.e15. PubMed ID: 32284255
[TBL] [Abstract][Full Text] [Related]
17. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study.
Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C
BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231
[TBL] [Abstract][Full Text] [Related]
18. "Real-world" outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma.
Drakaki A; Pantuck A; Mhatre SK; Dhillon PK; Davarpanah N; Degaonkar V; Surinach A; Chamie K; Grivas P
Urol Oncol; 2021 Jan; 39(1):76.e15-76.e22. PubMed ID: 32778476
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
Song W; Jeong JY; Jeon HG; Seo SI; Jeon SS; Choi HY; Lee HM; Sung HH
Int J Surg; 2019 Jun; 66():12-17. PubMed ID: 31018160
[TBL] [Abstract][Full Text] [Related]
20. Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma.
Adibi M; McCormick B; Economides MP; Petros F; Xiao L; Guo C; Shah A; Kamat AM; Dinney C; Navai N; Gao J; Siefker-Radtke A; Matin SF; Campbell MT
Clin Genitourin Cancer; 2022 Apr; 20(2):176-182. PubMed ID: 35039231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
